<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02401490</url>
  </required_header>
  <id_info>
    <org_study_id>BETA</org_study_id>
    <secondary_id>2014-004809-33</secondary_id>
    <nct_id>NCT02401490</nct_id>
  </id_info>
  <brief_title>Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy</brief_title>
  <acronym>BETA</acronym>
  <official_title>Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitari Vall d'Hebron Research Institute</source>
  <brief_summary>
    <textblock>
      To assess whether albumin administration after an episode of hepatic encephalopathy (≥ grade
      II) improves survival at 90 days (mortality endpoint treated as a composite endpoint death
      and/ or liver transplantation).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate whether albumin administration after an episode of hepatic encephalopathy (≥
      grade II) improves survival at 30, 90 and 180 days.

        -  to evaluate the effects of albumin on hepatic encephalopathy recurrence during the study
           period.

        -  To analyze whether albumin administration reduces hospitalization requirement.

        -  To study the effects of albumin on circulatory dysfunction index (mean arterial
           pressure, renal function, plasma vasopressor hormones).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival at 90 days. (The mortality endpoint is treated as a composite endpoint mortality and / or liver transplantation).</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival at 180 days.</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Hepatic Encephalopathy</condition>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Human albumin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>human albumin in the 24-48 hours after the hospitalization and at 48+/- 24 hours after the first dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>saline serum 0.9%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human albumin</intervention_name>
    <description>1.5gr/Kg/day at least in the 24-48 hours after the hospitalization and 1.0 gr/Kg/day at 72 hours after the first dose.</description>
    <arm_group_label>Human albumin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age between 18 and 85 years.

          2. Liver cirrhosis defined by previous clinical data or liver biopsy.

          3. Presence of an episode of acute hepatic encephalopathy of grade&gt; 2.

          4. Sign the informed consent

        Exclusion Criteria:

          1. Pregnant or breast-feeding.

          2. Terminal illness.

          3. Presence of Acute-on-chronic liver failure.

          4. Needing for intensive support measures.

          5. Active gastrointestinal bleeding.

          6. neurological or psychiatric comorbidity that hinders the assessment of hepatic
             encephalopathy.

          7. Clinical situations in which it is contraindicated to administer intravenous albumin.

          8. MELD score less than 15 or greater than 25 at the time of inclusion

          9. Any medical condition previous to patient inclusion in the study involving
             administration of albumin during a previous 7 day period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>German Soriano</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de la Santa Creu i Sant Pau. Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jordi Sanchez</last_name>
    <role>Principal Investigator</role>
    <affiliation>Corporació Sanitària Parc Taulí, Sabadell</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helena Masnou</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari Germans Trias i Pujol, Badalona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Núria Cañete</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital del Mar</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marta Martín</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Sant Joan Despí Moisès Broggi, Sant Joan Despí</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elsa Solà</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joan Genescà Ferrer</last_name>
    <email>jgenesca@vhebron.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Inmaculada Fuentes Camps, MD</last_name>
    <phone>934894113</phone>
    <phone_ext>4881</phone_ext>
    <email>usic@vhir.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Helena Masnou, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Corporació Sanitària Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jordi Sánchez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Sant Joan Despí Moisès Broggi</name>
      <address>
        <city>Sant Joan Despí</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marta Martín, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joan Genescà, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Meritxell Ventura, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elsa Solà, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>German Soriano, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nuria Cañete, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2015</study_first_submitted>
  <study_first_submitted_qc>March 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2015</study_first_posted>
  <last_update_submitted>December 27, 2017</last_update_submitted>
  <last_update_submitted_qc>December 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

